Impact of chemiluminescent enzyme immunoassay screening for human parvovirus B19 antigen in Japanese blood donors

Transfusion

Volumn 53, Issue 10 PART 2, 2013, Pages 2556-2566

  Sakata, Hidekatsu ^a,b,c,d,e   Matsubayashi, Keiji ^a,b,c,d,e   Ihara, Hiromi ^a,b,c,d,e   Sato, Shinichiro ^a,b,c,d,e   Kato, Toshiaki ^a,b,c,d,e   Wakisaka, Akemi ^a,b,c,d,e   Tadokoro, Kenji ^a,b,c,d,e   Yu, Mei Ying W ^a,b,c,d,e   Baylis, Sally A ^a,b,c,d,e   Ikeda, Hisami ^a,b,c,d,e   Takamoto, Shigeru ^a,b,c,d,e  

^a Japanese Red Cross Hokkaido Block Blood Center   (Japan)

^b Japanese Red Cross Society   (Japan)

^c Japanese Red Cross Blood Service Headquarters   (Japan)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIGEN; VIRUS DNA;

ALGORITHM; ANTIBODY SPECIFICITY; ARTICLE; BLOOD; BLOOD DONOR; ENZYME IMMUNOASSAY; EVALUATION STUDY; GENETICS; HUMAN; HUMAN PARVOVIRUS B19; IMMUNOLOGY; ISOLATION AND PURIFICATION; JAPAN; LUMINESCENCE; MASS SCREENING; METHODOLOGY; PARVOVIRUS INFECTION; PHYLOGENY; POLYMERASE CHAIN REACTION; SEROLOGY; STATISTICS; VIRUS LOAD; PARVOVIRIDAE INFECTIONS; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ALGORITHMS; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; BLOOD DONORS; DNA, VIRAL; HUMANS; IMMUNOENZYME TECHNIQUES; JAPAN; LUMINESCENT MEASUREMENTS; MASS SCREENING; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PHYLOGENY; POLYMERASE CHAIN REACTION; SEROLOGIC TESTS; VIRAL LOAD;

EID: 84891720318     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03949.x     Document Type: Article

References (38)

1. Blümel J, Burger R, Drosten C, Gröner A, Gürtler L, Heiden M, Hildebrandt M, Jansen B, Montag-Lessing T, Offergeld R, Pauli G, Seitz R, Schlenkrich U, Schottstedt V, Strobel J, Willkommen H, von König CH. Parvovirus B19-revised. Transfus Med Hemother 2010;37:339-50.
2. Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992;39:228-30.
3. Blümel J, Schmidt I, Effenberger W, Seitz H, Willkommen H, Brackmann HH, Löwer J, Eis-Hübinger AM. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002;42:1473-81.
4. Wu CG, Mason B, Jong J, Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MW. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 2005; 45:1003-10.
5. Sato H, Takakura F, Kojima E, Fukada K, Okochi K, Maeda Y. Screening of blood donors for human parvovirus B19. Lancet 1995;346:1237-8.
6. Sakata H, Ihara H, Sato S, Kato T, Ikeda H, Sekiguchi S. Efficiency of donor screening for human parvovirus B19 by the receptor-mediated hemagglutination assay method. Vox Sang 1999;77:197-203.
7. Sekiguchi S, Sato S, Kato T. Human parvovirus B19 DNA detected by receptor-mediated hemagglutination assay of pooled plasma for fractionation. Transfusion 1998;38: 108-9.
8. Takeda Y, Wakisaka A, Noguchi K, Murozuka T, Katsubayashi Y, Matsumoto S, Tomono T, Nishioka K. Receptormediated haemagglutination screening and reduction in the viral load of parvovirus B19 DNA in immunopurified Factor VIII concentrate (Cross Eight M). Vox Sang 2001;81: 266-8.
9. Council of Europe. Human anti-D immunoglobulin, monograph 0557. In: European Pharmacopoeia. 6th ed. Strasbourg, France: Council of Europe; 2008.
10. Council of Europe. Human anti-D immunoglobulin for intravenous administration, monograph 1527. In: European Pharmacopoeia. 6th ed. Strasbourg, France: Council of Europe; 2008.
11. Council of Europe. Human plasma (pooled and treated for virus inactivation), monograph 1646. In: European Pharmacopoeia. 6th ed. Strasbourg, France: Council of Europe; 2008.
12. U.S. Food and Drug Administration. Guidance for industry. Nucleic acid testing (NAT) to reduce the possible risk of human parvovirus B19 transmission by plasmaderived products. 2009. [cited 2012 Jun 29]. Available from: URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm078510.pdf
13. Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, Garbarg-Chenon A. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002;76:9124-34.
14. Candotti D, Etiz N, Parsyan A, Allain JP. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol 2004;78:12169-78.
15. Parsyan A, Szmaragd C, Allain JP, Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J Gen Virol 2007;88:428-31.
16. Sanabani S, Neto WK, Pereira J, Sabino EC. Sequence variability of human erythroviruses present in bone marrow of Brazilian patients with various parvovirus B19-related hematological symptoms. J Clin Microbiol 2006;44:604-6.
17. Norja P, Hokynar K, Aaltonen LM, Chen R, Ranki A, Partio EK, Kiviluoto O, Davidkin I, Leivo T, Eis-Hübinger AM, Schneider B, Fischer HP, Tolba R, Vapalahti O, Vaheri A, Söderlund-Venermo M, Hedman K. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci U S A 2006; 103:7450-3.
18. Toan NL, Duechting A, Kremsner PG, Song H, Ebinger M, Aberle S, Binh VQ, Duy DN, Torresi J, Kandolf R, Bock CT. Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients. J Gen Virol 2006;87:2941-9.
19. Hübschen JM, Mihneva Z, Mentis AF, Schneider F, Aboudy Y, Grossman Z, Rudich H, Kasymbekova K, Sarv I, Nedeljkovic J, Tahita MC, Tarnagda Z, Ouedraogo JB, Gerasimova AG, Moskaleva TN, Tikhonova NT, Chitadze N, Forbi JC, Faneye AO, Otegbayo JA, Charpentier E, Muller CP. Phylogenetic analysis of human parvovirus B19 sequences from eleven different countries confirms the predominance of genotype 1 and suggests the spread of genotype 3b. J Clin Microbiol 2009;47:3735-8.
20. Council of Europe. Nucleic acid amplification techniques. 07/2010:20621. In: European Pharmacopoeia. 7th ed. Strasbourg, France: Council of Europe; 2011.
21. Cohen BJ, Gandhi J, Clewley JP. Genetic variants of parvovirus B19 identified in the United Kingdom: implications for diagnostic testing. J Clin Virol 2006;36:152-5.
22. Japanese Red Cross Society. Haemovigilance by JRCS. 2008. [cited 2012 Jun 29]. Available from: URL: http://www.jrc.or.jp/vcms-lf/anzen-HVreport2008-en. pdf
23. Koppelman MH, Rood IG, Fryer JF, Baylis SA, Cuypers HT. Parvovirus B19 genotypes 1 and 2 detection with real-time polymerase chain reaction assays. Vox Sang 2007;93:208-15.
24. Baylis SA, Shah N, Minor PD. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. J Virol Methods 2004;121:7-16.
25. Candotti D, Danso K, Parsyan A, Dompreh A, Allain JP. Maternal-fetal transmission of human parvovirus B19 genotype 3. J Infect Dis 2006;194:608-11.
26. Baylis SA, Ma L, Padley DJ, Heath AB, Yu MW; the Collaborative Study Group. Collaborative study to establish a World Health Organization International Genotype Panel for parvovirus B19 DNA nucleic acid amplification technology (NAT)-based assays. Vox Sang 2012;102:204-11.
27. Infectious Disease Surveillance Center. Erythema infectiosum reported per sentinel weekly. 2012. [cited 2012 Jun 29]. Available from: URL: http://idsc.nih.go.jp/idwr/kanja/weeklygraph/07parvo-e.html
28. Thompson JD, Higgins DG, Gibson TJ, Clustal W. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-80.
29. Ekman A, Hokynar K, Kakkola L, Kantola K, Hedman L, Bondén H, Gessner M, Aberham C, Norja P, Miettinen S, Hedman K, Söderlund-Venermo M. Biological and immunological relations among human parvovirus B19 genotypes 1 to 3. J Virol 2007;81:6927-35.
30. Kooistra K, Mesman HJ, de Waal M, Koppelman MH, Zaaijer HL. Epidemiology of high-level parvovirus B19 viraemia among Dutch blood donors, 2003-2009. Vox Sang 2011;100:261-6.
31. Kleinman SH, Glynn SA, Lee TH, Tobler LH, Schlumpf KS, Todd DS, Qiao H, Yu MW, Busch MP; National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II (NHLBI REDS-II). A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009;114:3677-83.
32. Matsukura H, Shibata S, Tani Y, Shibata H, Furuta RA. Persistent infection by human parvovirus B19 in qualified blood donors. Transfusion 2008;48:1036-7.
33. Rinckel LA, Buno BR, Gierman TM, Lee DC. Discovery and analysis of a novel parvovirus B19 Genotype 3 isolate in the United States. Transfusion 2009;49:1488-92.
34. Suzuki M, Yoto Y, Ishikawa A, Tsutsumi H. Analysis of nucleotide sequences of human parvovirus B19 genome reveals two different modes of evolution, a gradual alteration and a sudden replacement: a retrospective study in Sapporo, Japan, from 1980 to 2008. J Virol 2009;83:10975-80
35. Yu MW, Alter HJ, Virata-Theimer ML, Geng Y, Ma L, Schechterly CA, Colvin CA, Luban NL. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion 2010;50:1712-21.
36. Hourfar MK, Mayr-Wohlfart U, Themann A, Sireis W, Seifried E, Schrezenmeier H, Schmidt M. Recipients potentially infected with parvovirus B19 by red blood cell products. Transfusion 2011;51:129-36.
37. Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro K. Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion 2011;51:1887-95.
38. Koppelman MH, Swieten PV, Cuijpers HT. Real-time polymerase chain reaction detection of parvovirus B19 DNA in blood donations using a commercial and an in-house assay. Transfusion 2011;51:1346-54.